Angiotensin II receptor blockers and risk of cancer: Cause for concern?

American Journal of Kidney Diseases

Volumn 57, Issue 1, 2011, Pages 7-10

  Rahbari Oskoui, Frederic ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ACUTE HEART INFARCTION; AGING; BRAIN ISCHEMIA; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEMOGRAPHY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GRAFT RECIPIENT; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; KIDNEY GRAFT; MONOTHERAPY; NEOPLASM; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SKIN CANCER; STROKE;

EID: 78650524244     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.09.012     Document Type: Editorial

References (17)

1. I. Ichikawi, and R.C. Harris Angiotensin actions in the kidney: renewed insight into the old hormone Kidney Int 40 4 1991 583 596
2. T. Rosenthal, and I. Gavras Angiotensin inhibition and malignancies: a review J Hum Hypertens 23 10 2009 623 635
3. F. Deshayes, and C. Nahmias Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16 7 2005 293 299
4. R.W. Colman Regulation of angiogenesis by the kallikrein-kinin system Curr Pharm Des 12 21 2006 2599 2607
5. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 9386 2003 759 766 (Pubitemid 37093915)
6. I. Sipahi, S.M. Debanne, D.Y. Rowland, D.I. Simon, and J.C. Fang Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol 11 7 2010 627 636
7. ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 15 2008 1547 1559
8. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 9644 2008 1174 1183
9. B. Dahlf, R.B. Devereux, S.E. Kjeldsen LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 9311 2002 995 1003 (Pubitemid 34286536)
10. S. Yusuf, H.C. Diener, R.L. Sacco PRoFESS Study Group Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 12 2008 1225 1237
11. J.B. Christian, K.L. Lapane, A.L. Hume, C.B. Eaton, M.A. Weinstock VATTC Trial Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial J Natl Cancer Inst 100 17 2008 1223 1232
12. L. Moscarelli, M. Zanazzi, and G. Mancini Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients Clin Nephrol 73 6 2010 439 445
13. S. Wilop, S. von Hobe, M. Crysandt, A. Esser, R. Osieka, and E. Jost Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy J Cancer Res Clin Oncol 135 10 2009 1429 1435
14. J.C. Bailar III The promise and problems of meta-analysis N Engl J Med 337 8 1997 559 561
15. M. Pahor, J.M. Guralnik, and L. Ferrucci Calcium-channel blockade and incidence of cancer in aged populations Lancet 348 9026 1996 493 497
16. J.A. Staessen, R. Fagard, L. Thijs Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension Lancet 350 9080 1997 757 764
17. S.A. Birkeland, H. Løkkegaard, and H.H. Storm Cancer risk in patients on dialysis and after renal transplantation Lancet 355 9218 2000 1886 1887